Financials and Corporate

The acquisition of the anti-C5aR, a first-in-class clinical-stage antibody, announced on June 2, 2017, is now finalized; The 3,343,748 new ordinary shares have been issued to Novo Nordisk A/S at a...

All proposed resolutions were voted according to management’s recommendations; Bpifrance Participations, represented by Maïlys Ferrere, and Pr. Jean-Charles Soria were appointed to the Supervisory...

Proposals to appoint Supervisory board members and renew members’ mandates at the Annual General Meeting. Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) will hold its Annual...

Cash, cash equivalents and financial assets of the Company amounted to €223.8 million* ; Additional clinical data expected later in 2017. Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421...

Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “AMF”) charter, Innate...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that the French version of its 2016 Reference document was filed with the Autorités des Marchés Financiers (AMF)...

Cash, cash equivalents and financial instruments* amounted to €230.7m (million euros) as of December 31, 2016 Revenue and other income amounted to €65.7m (€25.1m in 2015), including $15m (€13.8m)...

The study did not meet the primary efficacy endpoint Study confirms the safety profile of lirilumab as a monotherapy Broad clinical program ongoing, investigating lirilumab in a variety of tumor...